Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Research & Development (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Research & Development data on record, last reported at $85.1 million in Q4 2025.

  • For Q4 2025, Research & Development rose 27.77% year-over-year to $85.1 million; the TTM value through Dec 2025 reached $332.1 million, up 38.27%, while the annual FY2025 figure was $332.1 million, 38.27% up from the prior year.
  • Research & Development reached $85.1 million in Q4 2025 per CRNX's latest filing, down from $90.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $90.5 million in Q3 2025 and bottomed at $17.6 million in Q1 2021.
  • Average Research & Development over 5 years is $47.8 million, with a median of $42.2 million recorded in 2023.
  • Peak YoY movement for Research & Development: skyrocketed 62.5% in 2021, then grew 23.17% in 2023.
  • A 5-year view of Research & Development shows it stood at $24.6 million in 2021, then skyrocketed by 50.35% to $37.0 million in 2022, then grew by 23.22% to $45.6 million in 2023, then soared by 46.04% to $66.6 million in 2024, then rose by 27.77% to $85.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $85.1 million in Q4 2025, $90.5 million in Q3 2025, and $80.3 million in Q2 2025.